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Implications	 for	Nursing	
Care
Asthma	Chronic	Obstructive	Pulmonary	Disease	Overlap	Syndrome	
Kimberly	Babich-Speck	MBA,	BSN,	RN
Introduction
Throughout	 recent	years,	asthma	and	chronic	obstructive	pulmonary	 disease	(COPD)	 have	been	viewed	as	two	separate	diseases,	with	two	separate	pathophysiologies,	and	 two	different	treatment	plans,	essentially	ignoring	the	possibility	of	a	dual	diagnosis.	(Barrecheguren,	 Esquinas,	&	Mirvitlles,	2015).	 In	2014	 the	Global	Initiative	for	Chronic	Lung	 Disease	(GOLD)	and	Global	Initiative	for	Asthma	(GINA)	acknowledged	that	patients	could	indeed	have	both	pathophysiologies	of	COPD	and	asthma	(GOLD	&	GINA,	2015).	The	GOLD	and	GINA	collaboration	led	to	a	consensus	description	of	what	is	referred	 to	as	the	asthma-COPD	overlap	syndrome	(ACOS)	 (GOLD	&	GINA,	2015).	Asthma	is	defined	as	a	heterogeneous	disease,	usually	characterized	by	chronic	airway	inflammation	(GOLD	&	GINA,	2015).	 It	 is	defined	by	 the	history	of	respiratory	symptoms	such	as	wheeze,	shortness	of	breath,	 chest	tightness	and	cough	 that	vary	over	 time	and	 in	intensity,	together	with	variable	expiratory	airflow	limitation	(GINA,	2017).	 COPD	 is	defined	as	a	common	preventable	and	 treatable	disease,	characterized	by	persistent	airflow	limitation	that	is	usually	progressive	and	associated	with	enhanced	chronic	inflammatory	responses	 in	the	airways	and	 the	 lungs	to	noxious	particles	or	gases	(GOLD,	2017).	 ACOS	 is	characterized	by	persistent	airflow	limitation	with	several	features	usually	associated	with	asthma	and	several	features	usually	associated	with	COPD	(GOLD	&	GINA,	2015).	 	The	prevalence	of	ACOS	in	patients	diagnosed	with	COPD	 is	approximately	20%	 and	unfortunately	 is	characterized	by	more	 frequent	exacerbations	(Karampitsakos	&	Gourgoulianis,	2016).	Patients	with	ACOS	are	 typically	younger	with	higher	comorbidities,	disabilities,	hospitalizations,	and	ED	visitations	compared	 to	COPD	alone.	(Kumbhare,	Pleasants,	Ohar,	&	Strange,	2016).	 If	the	clinician	does	not	take	the	 time	to	correctly	identify	the	disease	behind	the	respiratory	 traits,	 the	patient	may	be	missing	appropriate	 treatments,	which	could	 lead	to	more	 frequent	exacerbations.		
Underlying	Pathophysiology References
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Figure	1.	Hypothetical	 course	of	lung	function	in	chronic	obstructive	pulmonary	disease	(COPD)	and	
asthma	 (Postma	&	Rabe,	 2015).
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Significance	of	Pathophysiology
Table	1.	Stepwise	Approach	 to	Care	 (GINA,	2017).
ACOS	pathophysiology	 is	speculative	and	contains	several	different	clinical	phenotypes	and	several	different	mechanisms	(GINA,	2017).	 ACOS	involves	inflammatory	processes	that	lead	to	 respiratory	remodeling,	 reactive	airways,	tissue	damage	and	lung	hyperinflation.	The	inflammatory	processes	include	the	asthma-like	eosinophilic	inflammation,	yet	the	COPD-like	neutrophilic	sputum	production	 may	be	present	 (Sin,	2017).	 A	type	2	 (T2)	helper	cell	inflammatory	pathway	seen	in	asthma	has	been	 found	 in	some	COPD	patients,	which	brings	speculation	that	these	are	actually	ACOS	patients	(Sin,	2017).	 A	proinflammatory	proteolytic	 cascade	leads	to	lung	tissue	breakdown	and	mild	centrilobular	emphysema	not	easily	detectable	by	lung	CAT	scans,	and	not	a	true	 feature	of	stand-alone	asthma,	yet	seen	in	ACOS	patients	(Gelb,	Yamamoto,	Verbeken,	 &	Nadel,	2015).	 Additionally,	ACOS	patients	show	less	emphysema	burden	 than	pure	 COPD	patients	(Sin,	2017).	 These	latter	mentioned	changes	cause	a	loss	of	lung	elastic	recoil	and	 therefore	hyperinflation	of	the	 lungs	(Gelb,	Yamamoto,	Verbeken,	 &	Nadel,	2015).	
Patients	with	ACOS	often	are	not	given	appropriate	 treatment	because	ACOS	patients	are	being	diagnosed	either	with	COPD	or	with	asthma,	leaving	part	of	 their	underlying	disease	process	untreated	 (Postma	&	Klaus,	2015).	 Because	the	majority	of	patients	with	COPD	are	diagnosed	in	 the	primary	care	setting,	the	 	primary	care	nurse	practitioner	(NP)	will	need	to	have	awareness	of	ACOS	characteristics	and	a	willingness	to	screen	for	airway	disease	in	at-risk	patients.	The	primary	care	NP	must	ensure	proper	 training	for	 the	staff	members	on	calibration	of	the	office	based	spirometry	equipment,	 and	ensure	 the	staff	members	administering	the	spirometry	testing	have	proper	 patient	 testing	technique.	With	the	ACOS	being	a	new	diagnosis	based	on	features	of	 two	other	diseases,	it	may	seem	to	be	easier	for	the	NP	 to	simply	“treat	 the	traits”	of	the	disease.	Caution	 is	advised	against	treating	 the	traits,	and	 instead	 to	discern	the	underlying	 disease	process	because	ACOS	usually	has	co-morbidities,	and	 treating	 the	traits	can	lead	to	polypharmacy	 (Sin,	2017).	Because	ACOS	patients	report	a	higher	burden	 of	 self	care	and	have	a	higher	hospitalization	rate,	nursing	care	will	have	to	include	assuring	 the	ACOS	patient	receives	timely	access	to	follow	up	care,	assuring	the	patient	has	transportation	 to	 the	appointment,	the	ability	to	access	medications,	has	medication	device	training	,	 and	medication	reconciliation	at	each	visit	(Kumbhare,	Pleasants,	Ohar,	&	Strange,	2016).	Consideration	should	be	given	to	the	need	 for	homecare	nursing	visitation	to	assess	the	home	environment	 for	possible	triggers,	provide	additional	medication	device	training,	assess	the	social	support	system,	and	functional	abilities	in	the	home.	
Signs	and	symptoms	of	ACOS	involve	signs	and	symptoms	of	both	asthma	and	COPD:
Inflammation	in	asthma	is	affiliated	with	increases	in	CD4+	T-lymphocytes	and	eosinophils.	Inflammation	in	COPD	 is	characterized	by	 increases	in	CD8+	T-lymphocytes,	neutrophils,	 and	macrophages	(Wurst,	Kelly-Reif,	Bushnell,	Pascoe,	&	Barnes,	2016).	 	Treatments	for	 the	two	diseases	are	dictated	by	 the	underlying	pathophysiologies.	ACOS,	having	a	mixture	of	 the	two,	has	a	unique	pharmacotherapy	 that	requires	early	use	of	inhaled	corticosteroids,	which	are	not	 typically	used	in	COPD	until	later	 in	disease	progression	in	stage	D	(GOLD,	2017).
COPD	and	asthma	are	prevalent	worldwide	diseases.	ACOS,	the	disease	that	combines	characteristics	of	these	diseases,	is	no	longer	being	 ignored.	ACOS	is	a	difficult	disease	to	diagnose	and	comes	with	a	high	health	care	economic	cost	to	society.	Understanding	 	and	management	of	ACOS	will	improve	as	the	disease	is	increasingly	studied.	Patient	education	 for	 self	management	to	improve	outcomes	and	 	avoid	hospitalization	will	become	a	large	part	of	the	nurse’s	responsibilities	when	caring	for	 the	ACOS	patient.	 	
Asthma	signs	and	symptoms		include:
• Variable	expiratory	airflow
• Wheezing
• Shortness	of	breath
• Chest	 tightness
• Cough
• due	 to	bronchoconstriction,	airway	wall	thickening,	and	 increased	mucus	(GINA,	2017).	
COPD	signs	and	symptoms		include:
• Dyspnea	progressive	over	 time,	worse	with	exercise	and	persistent.
• Chronic	cough	 	w	or	w/o	sputum
• Recurrent	wheeze
• Lower	respiratory	 tract	infections
• History	of	exposure	 to	smoke,	dusts,	vapors,	 fumes,	or	gases.
• Family	history	of	COPD	and/or	childhood	factors	(GOLD,	2017).
1. Using	the	signs	and	symptoms	of	asthma	and	COPD,	assemble	the	features	that,	when	present,	 most	favour	a	diagnosis	of	typical	asthma	or	 typical	COPD.2. Compare	 the	number	 of	features	on	each	side.	3. If	the	patient	has	≥3	 features	of	either	asthma	or	COPD,	 there	 is	a	strong	 likelihood	that	this	is	the	correct	diagnosis.	4. When	a	patient	has	a	 similar	number	of	features	of	both	asthma	and	COPD,	consider	the	diagnosis	of	asthma-COPD	overlap	 (GINA,	2017).	
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